Gz402669    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
222一次性ネフローゼ症候群3

222. 一次性ネフローゼ症候群 [臨床試験数:234,薬物数:241(DrugBank:78),標的遺伝子数:59,標的パスウェイ数:185
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 234 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2012-002365-35-DE
(EUCTR)
15/07/201311/03/2013A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis Focal segmental glomerulosclerosis
MedDRA version: 14.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Not possible to specify
Product Name: Fresolimumab
Product Code: GC1008
INN or Proposed INN: Fresolimumab
Other descriptive name: GZ402669
Genzyme CorporationNULLNot RecruitingFemale: yes
Male: yes
125Phase 2France;United States;Brazil;Spain;Germany;Italy
2EUCTR2012-002365-35-IT
(EUCTR)
22/05/201320/03/2013A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis Focal segmental glomerulosclerosis
MedDRA version: 15.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Not possible to specify
Product Name: Fresolimumab
Product Code: GC1008
INN or Proposed INN: Fresolimumab
Other descriptive name: GZ402669
Genzyme CorporationNULLNot RecruitingFemale: yes
Male: yes
125Phase 2France;United States;Brazil;Spain;Germany;Italy
3EUCTR2012-002365-35-ES
(EUCTR)
19/04/201309/04/2013A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis Focal segmental glomerulosclerosis
MedDRA version: 14.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Not possible to specify
Product Name: Fresolimumab
Product Code: GC1008
INN or Proposed INN: Fresolimumab
Other descriptive name: GZ402669
Genzyme CorporationNULLNot RecruitingFemale: yes
Male: yes
125Phase 2France;United States;Brazil;Spain;Germany;Italy